GenFleet Therapeutics-B (02595): Multiple innovative combination therapies of the oral pan-RAS inhibitor GFH276 have recently received clinical trial approval, conducting clinical research on first-line and later-line major indication tumor types in China or overseas.

Zhitong Finance APP news, GenFleet Therapeutics-B (02595) issued an announcement that since the third quarter of this year, multiple innovative combination therapies of the oral pan-RAS inhibitor GFH276 have obtained clinical trial approvals issued by China's CDE, or completed clinical trial filings with Australia's TGA. The related studies cover first-line and later-line treatment of multiple major-indication tumor types with RAS mutations, among which some trials have already enrolled patients at multiple dose levels.